Search

Your search keyword '"Kosiorek, Heidi"' showing total 974 results
Start Over Author "Kosiorek, Heidi"
974 results on '"Kosiorek, Heidi"'

203. Oral idasanutlin in patients with polycythemia vera

Author

Mascarenhas, John, primary, Lu, Min, additional, Kosiorek, Heidi, additional, Virtgaym, Elizabeth, additional, Xia, Lijuan, additional, Sandy, Lonette, additional, Mesa, Ruben, additional, Petersen, Bruce, additional, Farnoud, Noushin, additional, Najfeld, Vesna, additional, Rampal, Raajit, additional, Dueck, Amylou, additional, and Hoffman, Ronald, additional

Published
2019
Full Text
View/download PDF

204. Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer

Author

McDonald, Bradon R., primary, Contente-Cuomo, Tania, additional, Sammut, Stephen-John, additional, Odenheimer-Bergman, Ahuva, additional, Ernst, Brenda, additional, Perdigones, Nieves, additional, Chin, Suet-Feung, additional, Farooq, Maria, additional, Mejia, Rosa, additional, Cronin, Patricia A., additional, Anderson, Karen S., additional, Kosiorek, Heidi E., additional, Northfelt, Donald W., additional, McCullough, Ann E., additional, Patel, Bhavika K., additional, Weitzel, Jeffrey N., additional, Slavin, Thomas P., additional, Caldas, Carlos, additional, Pockaj, Barbara A., additional, and Murtaza, Muhammed, additional

Published
2019
Full Text
View/download PDF

211. DIPNECH: The Mayo experience.

Author

Almquist, Daniel, primary, Cabrera, Arriana, additional, Sonbol, Mohamad Bassam, additional, Kosiorek, Heidi E., additional, Halfdanarson, Thorvardur Ragnar, additional, Ross, Helen J., additional, Paripati, Harshita, additional, and Jaroszewski, Dawn E., additional

Published
2019
Full Text
View/download PDF

216. Ruxolitinib Therapy Followed by Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation for Myelofibrosis: Myeloproliferative Disorders Research Consortium 114 Study

Author

Gupta, Vikas, primary, Kosiorek, Heidi E., additional, Mead, Adam, additional, Klisovic, Rebecca B., additional, Galvin, John P., additional, Berenzon, Dmitriy, additional, Yacoub, Abdulraheem, additional, Viswabandya, Auro, additional, Mesa, Ruben A., additional, Goldberg, Judith, additional, Price, Leah, additional, Salama, Mohamed E., additional, Weinberg, Rona Singer, additional, Rampal, Raajit, additional, Farnoud, Noushin, additional, Dueck, Amylou C., additional, Mascarenhas, John O., additional, and Hoffman, Ronald, additional

Published
2019
Full Text
View/download PDF

218. Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis

Author

Mascarenhas, John, primary, Baer, Maria R., additional, Kessler, Craig, additional, Hexner, Elizabeth, additional, Tremblay, Douglas, additional, Price, Leah, additional, Sandy, Lonette, additional, Weinberg, Rona, additional, Pahl, Heike, additional, Silverman, Lewis R., additional, Goldberg, Judith D., additional, Kosiorek, Heidi, additional, Dueck, Amylou C., additional, and Hoffman, Ronald, additional

Published
2019
Full Text
View/download PDF

221. Symptom burden and quality of life in patients with high-risk essential thrombocythaemia and polycythaemia vera receiving hydroxyurea or pegylated interferon alfa-2a: a post-hoc analysis of the MPN-RC 111 and 112 trials

Author

Mazza, Gina L, Mead-Harvey, Carolyn, Mascarenhas, John, Yacoub, Abdulraheem, Kosiorek, Heidi E, Hoffman, Ronald, Dueck, Amylou C, and Mesa, Ruben A

Abstract

Patients with essential thrombocythaemia or polycythaemia vera have several symptoms that can worsen their quality of life. We aimed to assess how symptom burden changes over time with cytoreductive therapy.

Published
2022
Full Text
View/download PDF

222. Perioperative Diabetes Insipidus Caused by Anesthetic Medications: A Review of the Literature

Author

Van Decar, Lauren M., Reynolds, Emily G., Sharpe, Emily E., Harbell, Monica W., Kosiorek, Heidi E., and Kraus, Molly B.

Abstract

Diabetes insipidus (DI) is an uncommon perioperative complication that can occur secondary to medications or surgical manipulation and can cause significant hypovolemia and electrolyte abnormalities. We reviewed and evaluated the current literature and identified 29 cases of DI related to medications commonly used in anesthesia such as propofol, dexmedetomidine, sevoflurane, ketamine, and opioids. This review summarizes the case reports and frequency of DI with each medication and presents possible pathophysiology. Medication-induced DI should be included in the differential diagnosis when intraoperative polyuria is identified. Early identification, removal of the agent, and treatment of intraoperative DI are critical to minimize complications.

Published
2022
Full Text
View/download PDF

224. Safety and efficacy of combined ruxolitinib and decitabine in accelerated and blast-phase myeloproliferative neoplasms

Author

Rampal, Raajit K., primary, Mascarenhas, John O., additional, Kosiorek, Heidi E., additional, Price, Leah, additional, Berenzon, Dmitriy, additional, Hexner, Elizabeth, additional, Abboud, Camille N., additional, Kremyanskaya, Marina, additional, Weinberg, Rona Singer, additional, Salama, Mohamed E., additional, Menghrajani, Kamal, additional, Najfeld, Vesna, additional, Sandy, Lonette, additional, Heaney, Mark L., additional, Levine, Ross L., additional, Mesa, Ruben A., additional, Dueck, Amylou C., additional, Goldberg, Judith D., additional, and Hoffman, Ronald, additional

Published
2018
Full Text
View/download PDF

227. Hormone Replacement Therapy Prescription after Premature Surgical Menopause.

Author

Garg, Nisha, Behbehani, Sadikah, Kosiorek, Heidi, and Wasson, Megan

Abstract

Study Objective: To assess hormone replacement therapy (HRT) prescription pattern in patients undergoing premature surgical menopause on the basis of surgical indication.Design: Retrospective cohort study.Setting: Academic tertiary care center.Patients: Surgically menopausal patients aged ≤45 years who underwent a minimally invasive hysterectomy with salpingo-oophorectomy.Interventions: HRT prescription in the 6-week postoperative period.Measurements and Main Results: A total of 63 patients met inclusion criteria. Of these, 52% (n = 33) were prescribed HRT in the 6-week postoperative period. Indications for surgical menopause included pelvic pain or endometriosis (31.7%), gynecologic malignancy (20.6%), BRCA gene mutation (17.4%), breast cancer (9.5%), Lynch syndrome (4.8%), and other (15.8%). In total, 80% of patients with pelvic pain, 25% with gynecologic malignancies, 45% with BRCA gene mutations, 33.3% with breast cancer, and 66.6% with Lynch syndrome used HRT postoperatively. In patients who used HRT postoperatively, 76% were offered preoperative HRT counseling. This is in contrast with those patients who did not use HRT postoperatively, of whom only 33% were offered HRT counseling (p <.001). Perioperative complications were not predictive of HRT use postoperatively. In patients who did not use HRT postoperatively, 13.3% used alternative nonhormonal therapy.Conclusion: In patients who underwent premature surgical menopause, 52% used HRT postoperatively. Patients with pelvic pain and Lynch syndrome were more likely to use HRT, whereas those with gynecologic or breast malignancies and BRCA gene mutations were less likely to use HRT. Preoperative HRT counseling was associated with postoperative HRT use. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

228. Same-Day Discharge After Mastectomy: Breast Cancer Surgery in the Era of ERAS®.

Author

Jogerst, Kristen, Thomas, Olivia, Kosiorek, Heidi E., Gray, Richard, Cronin, Patricia, Casey III, William, Rebecca, Alanna, Craner, Ryan, Young-Fadok, Tonia, and Pockaj, Barbara

Abstract

Background: Enhanced recovery after surgery (ERAS®) principles have been beneficial in major abdominal surgery. ERAS® was instituted in our breast surgery practice in 2017. The goal of this study was to evaluate the feasibility of outpatient mastectomies before and after ERAS®. Methods: A retrospective review of all mastectomies between 1/2013 and 6/2018 was performed. Patients receiving autologous flap reconstruction were excluded. The institution-specific ERAS® pathway began on February 1, 2017. Patient characteristics, operative intervention, and postoperative outcomes were compared between pre-ERAS® and post-ERAS® groups and between outpatient and inpatient subgroups. Continuous and categorical variables were compared using Wilcoxon rank-sum and Chi-square analyses. Results: A total of 487 patients were analyzed. Three hundred and forty-seven (71%) were prior to ERAS® and 140 after (29%). The two groups were not significantly different in background characteristics. Same-day discharge occurred in 58.6% of post-ERAS® patients versus 7.2% of pre-ERAS® patients (p < 0.001). Liposomal bupivacaine block was used for pain control more in the post-ERAS® group, 62.1% versus 6.1% (p < 0.001). Reconstruction type differed with 45.7% of the post-ERAS® group undergoing direct-to-implant reconstruction versus 34.3% of pre-ERAS® patients (p < 0.001) and with higher rates of submuscular implant and tissue expander placement in the pre-ERAS® versus post-ERAS® group (p < 0.001). Complications rates were lower in the post-ERAS® group versus pre-ERAS® group, 32.9% versus 52.4% (p < 0.001). The outpatient subgroup had higher rates of liposomal bupivacaine administration 74.4% versus 44.8% (p < 0.001). Baseline characteristics and complication rates did not differ between outpatient and admitted subgroups. Conclusion: ERAS® principles can be applied to breast cancer patients and allow for outpatient mastectomies with no increase in postoperative morbidity. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

229. Evaluation of NUC-1031: a first-in-class ProTide in biliary tract cancer.

Author

Arora, Mansi, Bogenberger, James M., Abdelrahman, Amro, Leiting, Jennifer L., Chen, Xianfeng, Egan, Jan B., Kasimsetty, Aradhana, Lenkiewicz, Elzbieta, Malasi, Smriti, Uson, Pedro Luiz Serrano, Nagalo, Bolni Marius, Zhou, Yumei, Salomao, Marcela A., Kosiorek, Heidi E., Braggio, Esteban, Barrett, Michael T., Truty, Mark J., and Borad, Mitesh J.

Subjects
BILIARY tract cancer, GALLBLADDER, CYTIDINE deaminase, ATP-binding cassette transporters, PEMETREXED, CISPLATIN
Abstract

Purpose: NUC1031 is a first-in-class ProTide, that is a gemcitabine pro-drug designed to overcome putative mechanisms of resistance, including decreased expression of hENT/hCNT transporters, absence of activating enzymes such as deoxycytidine kinase (dCK) and presence of degrading enzymes such as cytidine deaminase (CDA). We undertook comprehensive pre-clinical evaluation of NUC1031 in biliary tract cancer (BTC) models, given that gemcitabine/cisplatin is a standard first-line therapy in advanced BTC.Methods: Here, we compared the in vitro activity of NUC1031 in comparison to gemcitabine, validate putative mechanism(s) of action, assessed potential biomarkers of sensitivity or resistance, and performed combination studies with cisplatin. We also evaluated the in vivo efficacy of NUC1031 and gemcitabine using a CDA-high cholangiocarcinoma patient-derived xenograft (PDX) model.Results: In a panel of BTC cell lines (N = 10), NUC1031 had less potency than gemcitabine in multiple cellular assays. NUC1031 did not demonstrate evidence of greater synergy over gemcitabine in combination with cisplatin. Surprisingly, efficacy of both gemcitabine and NUC1031 was not found to be correlated with hENT/hCTN, dCK or CDA transcript levels. Gemcitabine and NUC1031 showed equivalent efficacy in a CDA-high PDX model in vivo contradicting the primary rationale of NUC1031 design.Conclusion: NUC1031 did not exhibit evidence of superior activity over gemcitabine, as a single-agent, or in combination with cisplatin, in either our in vivo or in vitro BTC models. Given that the largest Phase 3 study (ClinicalTrials.gov: NCT0314666) to date in BTC is underway (N = 828) comparing NUC1031/cisplatin to gemcitabine/cisplatin, our results suggest that a more conservative clinical evaluation path would be more appropriate. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

230. Depomedroxyprogesterone acetate therapy for hot flashes in survivors of breast cancer: no unfavorable impact on recurrence and survival.

Author

Ertz-Archambault, Natalie M., Rogoff, Lana B., Kosiorek, Heidi E., Ernst, Brenda J., Anderson, Karen S., Pockaj, Barbara A., Gray, Richard J., and Northfelt, Donald W.

Subjects
HOT flashes, CANCER patients, BREAST cancer, INSTITUTIONAL review boards, ACETATES, PROGRESSION-free survival, MEDROXYPROGESTERONE, RETROSPECTIVE studies, CASE-control method, PROGNOSIS, CANCER relapse, LONGITUDINAL method, BREAST tumors
Abstract

Purpose: Survivors of estrogen receptor-expressing breast cancer generally do not receive estrogen-based therapy for menopausal symptoms due to concern for provoking recurrence of disease. Single-dose depomedroxyprogesterone acetate has been shown to be among the most effective non-estrogen strategies for treatment of menopausal hot flashes, but long-term evidence for safety in survivors is lacking.Methods: We conducted an institutional review board approved, retrospective, case-control cohort study at a tertiary, academic referral center. Patients with estrogen receptor-expressing early-stage operable breast cancer who received depomedroxyprogesterone acetate for hot flashes between January 2005 and December 2012 were identified. We confirmed 75 patients who met strict inclusion criteria who were matched 1:1 with controls for age, stage of disease, HER2 status, and year of diagnosis. Overall survival, loco-regional recurrence-free survival, and progression-free survival assessments for cases were compared with controls.Results: Median follow-up duration was 68.4 months in cases and 57.6 months in controls. Estimated local-regional recurrence-free survival at 10 years was 97% (95% CI, 92-100%) in cases and 98% (95% CI, 95-100%) in controls. Estimated progression-free survival at 10 years was 89% (95% CI, 80-100%) in cases and 83% (95% CI, 73-95) in controls. The majority (75%) of case patients experienced satisfactory relief of hot flashes from depomedroxyprogesterone injection.Discussion: In this retrospective case-control study, we were unable to identify a detrimental effect of depomedroxyprogesterone acetate therapy for hot flashes in survivors of estrogen receptor-expressing breast cancer. Depomedroxyprogesterone acetate may be acceptable for management of hot flashes in this population. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

231. Early post-transplantation factors predict survival outcomes in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis.

Author

Jain, Tania, Kunze, Katie L., Mountjoy, Luke, Partain, Daniel K., Kosiorek, Heidi, Khera, Nandita, Hogan, William J., Roy, Vivek, Slack, James L., Noel, Pierre, Fauble, Veena D. S., Leis, Jose F., Sproat, Lisa, Tefferi, Ayalew, Patnaik, Mrinal M., Mesa, Ruben A., and Palmer, Jeanne

Subjects
MYELOFIBROSIS, CELL transplantation, BLOOD platelet transfusion, CHIMERISM, BONE marrow
Abstract

Factors predicting allogeneic hematopoietic cell transplantation (HCT) outcomes in myelofibrosis in the early post-HCT period have not been defined thus far. We attempt to study such factors that can help identify patients at a higher risk of relapse or death. This retrospective study included 79 patients who underwent first HCT for myelofibrosis at three centers between 2005 and 2016. Univariate analysis showed that red blood cell (RBC) transfusion dependence (HR 9.02, 95% CI 4.0–20.35), platelet transfusion dependence (HR 8.17, 95%CI 3.83–17.37), 100% donor chimerism in CD33 + cells (HR 0.21, 95%CI 0.07–0.62), unfavorable molecular status (HR 4.41, 95%CI 1.87–10.39), normal spleen size (HR 0.42, 95%CI 0.19–0.94), grade ≥ 2 bone marrow fibrosis (vs. grade ≤ 1; HR 2.7, 95%CI 1.1–6.93) and poor graft function (HR 2.6, 95%CI 1.22–5.53) at day +100 were statistically significantly associated with relapse-free survival (RFS). RBC transfusion dependence and unfavorable molecular status were also statistically significant in the multivariate analysis. Patients in whom both of these factors were present had a significantly worse RFS when compared to those with one or none. While limited by a small sample size, we demonstrate the significance of transfusion dependence and molecular status at day +100 in predicting outcomes. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

233. Efficacy of Combined Ruxolitinib and Decitabine in Patients with Accelerated and Blast-Phase Myeloproliferative Neoplasms: Results of a Phase II Study (MPN-RC 109 trial)

Author

Rampal, Raajit K., primary, Mascarenhas, John, additional, Kosiorek, Heidi E., additional, Bhave, Rupali, additional, Hexner, Elizabeth O., additional, Wang, Eunice S., additional, Gerds, Aaron T., additional, Heaney, Mark L, additional, Abboud, Camille N, additional, Kremyanskaya, Marina, additional, Berenzon, Dmitriy, additional, Odenike, Olatoyosi, additional, Virtgaym, Elizabeth, additional, Sandy, Lonette, additional, Weinberg, Rona Singer, additional, Najfeld, Vesna, additional, Salama, Mohamed E., additional, Levine, Ross L., additional, Mesa, Ruben A., additional, Dueck, Amylou C., additional, and Hoffman, Ronald, additional

Published
2018
Full Text
View/download PDF

234. Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)

Author

Mascarenhas, John, primary, Kosiorek, Heidi E., additional, Prchal, Josef T., additional, Rambaldi, Alessandro, additional, Berenzon, Dmitriy, additional, Yacoub, Abdulraheem, additional, Harrison, Claire N., additional, McMullin, Mary Frances, additional, Vannucchi, Alessandro M., additional, Ewing, Joanne, additional, O'Connell, Casey L., additional, Kiladjian, Jean-Jacques, additional, Mead, Adam J., additional, Winton, Elliott F., additional, Leibowitz, David S., additional, De Stefano, Valerio, additional, Arcasoy, Murat O., additional, Kessler, Craig M., additional, Catchatourian, Rosalind, additional, Rondelli, Damiano, additional, Silver, Richard T., additional, Bacigalupo, Andrea, additional, Nagler, Arnon, additional, Kremyanskaya, Marina, additional, Sandy, Lonette, additional, Salama, Mohamed E., additional, Najfeld, Vesna, additional, Tripodi, Joseph, additional, Weinberg, Rona Singer, additional, Price, Leah, additional, Goldberg, Judith D, additional, Rampal, Raajit K., additional, Mesa, Ruben A., additional, Dueck, Amylou C., additional, and Hoffman, Ronald, additional

Published
2018
Full Text
View/download PDF

236. Myeloproliferative Neoplasm Quality of Life (MPN-QOL) Study Group: MPN Experimental Assessment of Symptoms By Utilizing Repetitive Evaluation (MEASURE) Trial

Author

Gathany, Allison, primary, Scherber, Robyn M., additional, Girardo, Marlene, additional, Kosiorek, Heidi E., additional, Dueck, Amylou C., additional, Geyer, Holly, additional, Fauble, Veena D. S., additional, Vannucchi, Alessandro M., additional, Fuentes, Ana Kerguelen, additional, Andersen, Christen Lykkegaard, additional, Ejerblad, Elisabeth, additional, Birgegard, Gunnar, additional, Johansson, Peter L., additional, Andreasson, Bjorn, additional, Ross, David M, additional, Sackman, Federico, additional, Demory, Jean-Loup, additional, Tam, Constantine S., additional, Michiels, Jan J., additional, Radia, Deepti, additional, Ewing, Joanne, additional, Wadelin, Frances, additional, Lown, Robert N., additional, McMullin, Mary Frances, additional, Swe, Wunna, additional, Cullis, Jonathan O., additional, Sargant, Nigel, additional, Moreton, Paul, additional, Cargo, Catherine, additional, Sekhar, Mallika, additional, Shekouhi, Satareh, additional, and Mesa, Ruben A., additional

Published
2018
Full Text
View/download PDF

240. Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial

Author

Mesa, Ruben A., primary, Kosiorek, Heidi E., additional, Mascarenhas, John, additional, Prchal, Josef T., additional, Rambaldi, Alessandro, additional, Berenzon, Dmitriy, additional, Yacoub, Abdulraheem, additional, Harrison, Claire N., additional, McMullin, Mary Frances, additional, Vannucchi, Alessandro M., additional, Ewing, Joanne, additional, O'Connell, Casey L., additional, Kiladjian, Jean-Jacques, additional, Mead, Adam J., additional, Winton, Elliott F., additional, Leibowitz, David S., additional, De Stefano, Valerio, additional, Arcasoy, Murat O., additional, Kessler, Craig M., additional, Catchatourian, Rosalind, additional, Rondelli, Damiano, additional, Silver, Richard T., additional, Bacigalupo, Andrea, additional, Nagler, Arnon, additional, Kremyanskaya, Marina, additional, Sandy, Lonette, additional, Salama, Mohamed E., additional, Najfeld, Vesna, additional, Tripodi, Joseph, additional, Weinberg, Rona Singer, additional, Rampal, Raajit K., additional, Hoffman, Ronald, additional, and Dueck, Amylou C., additional

Published
2018
Full Text
View/download PDF

242. A Novel Combination of the mTORC1 Inhibitor Everolimus and the Immunomodulatory Drug Lenalidomide Produces Durable Responses in Patients With Heavily Pretreated Relapsed Lymphoma

Author

Padrnos, Leslie, primary, Ernst, Brenda, additional, Dueck, Amylou C., additional, Kosiorek, Heidi E., additional, Ginos, Brenda F., additional, Toro, Angela, additional, Johnston, Patrick B., additional, Habermann, Thomas M., additional, Leis, Jose F., additional, Mikhael, Joseph R., additional, Nowakowski, Grzegorz S., additional, Colgan, Joseph, additional, Porrata, Luis, additional, Ansell, Stephen M., additional, Witzig, Thomas E., additional, and Reeder, Craig, additional

Published
2018
Full Text
View/download PDF

244. Advantages of intensity modulated proton therapy during hippocampal avoidance whole brain radiation therapy

Author

Stoker, Joshua, primary, Vora, Sujay, additional, Patel, Ameet, additional, Grosshans, David, additional, Brown, Paul D., additional, Vern-Gross, Tamara, additional, Bues, Martin, additional, Daniels, Thomas, additional, Allred, Bryce, additional, Uejo, Arielle, additional, Kosiorek, Heidi, additional, Bruso, Marlene, additional, and Keole, Sameer, additional

Published
2018
Full Text
View/download PDF

245. Detection of residual disease after neoadjuvant therapy in breast cancer using personalized circulating tumor DNA analysis

Author

McDonald, Bradon R., primary, Contente-Cuomo, Tania, additional, Sammut, Stephen-John, additional, Odenheimer-Bergman, Ahuva, additional, Ernst, Brenda, additional, Perdigones, Nieves, additional, Chin, Suet-Feung, additional, Farooq, Maria, additional, Cronin, Patricia A., additional, Anderson, Karen S., additional, Kosiorek, Heidi E., additional, Northfelt, Donald W., additional, McCullough, Ann E., additional, Patel, Bhavika K., additional, Caldas, Carlos, additional, Pockaj, Barbara A., additional, and Murtaza, Muhammed, additional

Published
2018
Full Text
View/download PDF

247. Single dose versus multiple doses of rituximab for preemptive therapy of Epstein–Barr virus reactivation after hematopoietic cell transplantation

Author

Jain, Tania, primary, Kosiorek, Heidi E., additional, Grys, Thomas E., additional, Kung, Shu Ting, additional, Shah, Vishal S., additional, Betcher, Jeffrey A., additional, Slack, James L., additional, Leis, Jose F., additional, Khera, Nandita, additional, Noel, Pierre, additional, Palmer, Jeanne M., additional, and Sproat, Lisa Z., additional

Published
2018
Full Text
View/download PDF

248. Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective Study

Author

Jain, Tania, primary, Kosiorek, Heidi E., additional, Kung, Shu T., additional, Shah, Vishal S., additional, Dueck, Amylou C., additional, Gonzalez-Calle, Veronica, additional, Luft, Susan, additional, Reeder, Craig B., additional, Adams, Roberta, additional, Noel, Pierre, additional, Larsen, Jeremy T., additional, Mikhael, Joseph, additional, Bergsagel, Leif, additional, Stewart, A. Keith, additional, and Fonseca, Rafael, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results